Home | Welcome to Contract Pharma   
Last Updated Tuesday, September 2 2014
Print

Financial Report: Anacor Pharmaceuticals



Published May 10, 2013
Related Searches: R&D
Anacor Pharmaceuticals

1Q Revenues: $1.7 million (-29%)

1Q Loss: $15.1 million (loss of $14.3 million in 1Q12)

Comments: Contract revenue decline was due to a decrease in research work performed under R&D agreements. R&D expenses were $11.2 million, down 12%. On April 5, 2013, the company entered a research agreement with the Gates Foundation to discover drug candidates to treat elephantiasis and tuberculosis. Anacor will receive as much as $17.7 million over three years for research activities.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On